Top Markets
#1 DogBull DogBull +45.35%
#2 TRIA TRIA +21.90%
#3 MetaDAO MetaDAO +18.06%
#4 Siren Siren +15.84%
#5 wojak wojak +15.30%
#6 Quack AI Quack AI +13.63%
#7 Dash Dash +12.16%
#8 TDCCP TDCCP +9.66%
#9 Unicorn Unicorn +9.27%
#10 Vana Vana +7.86%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc.

ODTC
Rank in Stocks #18163
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and... Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Share Price
$150,000
Last synced: 2025-02-11
Market Cap
$210.38M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Odonate Therapeutics, Inc. (ODTC)

Category

Healthcare
Revenue for Odonate Therapeutics, Inc. (ODTC)
Revenue in Sep 2026 TTM: 0
According to Odonate Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Odonate Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH